Skip to content
Home/Companies/Biotech/Bindbridge
Bindbridge

Bindbridge

Biotech·United Kingdom·Active·New
Entry
2026
Hold
New
Status
Active

Who owns Bindbridge?

Bindbridge is a British Biotech company, currently owned by Nucleus Capital since 2026.

Hand-verified · updated 2026-07-03

Open JSON · CC-BY
Nucleus Capital
Investor
Nucleus Capital
Nucleus Capital II · 2024 · VC

Key facts

HQUnited Kingdom
SectorBiotech
StatusActive
Websitewww.bindbridge.com

More from Nucleus Capital II

Other portfolio companies in the same fund.

Triple Bio
Triple Bio
Active
BiotechNetherlands· 2026
AtmoCooling
Active
ClimateTechUS· 2025
Ruby Bio
Active
BiotechUS· 2025
Spark E-Fuels
Active
ClimateTechGermany· 2025
Telura
Telura
Active
ClimateTechGermany· 2025
Apoha
Active
Deep TechUK· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Bindbridge?

Bindbridge is currently owned by Nucleus Capital, through Nucleus Capital II, since 2026.

When did Nucleus Capital acquire Bindbridge?

Nucleus Capital acquired Bindbridge in 2026.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue